

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 91523

Title: New avenues for the treatment of immunotherapy-resistant pancreatic cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 07225840 Position: Peer Reviewer Academic degree: MSc

Professional title: Research Fellow

Reviewer's Country/Territory: India

Author's Country/Territory: Brazil

Manuscript submission date: 2023-12-29

Reviewer chosen by: AI Technique

Reviewer accepted review: 2024-01-05 05:12

Reviewer performed review: 2024-01-17 06:45

Review time: 12 Days and 1 Hour

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors have quite beautifully prepared the manuscript. Incorporating almost all the scientific endeavors related to immunotherapy in Pancreatic Cancer. However, two things need to be considered- 1. It will be better if the authors add a separate section for the availability, challenges and efficacy of chemotherapy, radiotherapy and surgical intervention related to pancreatic cancer. 2. Structurally, the authors should work on connecting the paragraphs so that the link between different sections is more specific and do not appear to be abrupt.